Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLOW: zolbetuximab plus CAPOX versus placebo plus CAPOX in first-line CLDN18.2-positive HER2-negative advanced gastric/GEJ adenocarcinoma
jRCT2080224166Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 4, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing zolbetuximab + CAPOX with placebo + CAPOX (2 arms). Started Nov 2018; status: completed.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080224166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224166.